function of glp 1 Glucagon-like peptide 1(GLP-1) receptor agonists in the management the patient with type 2diabetes mellitus and chronic kidney disease: an approach for the nephrologist GLP-1 actions and target organs.

Low birth weight, according to human epidemiological studies, is linked to an increased risk of adult-onset cardiovascular and metabolic diseases such as hypertension, coronary heart disease, obesity, and type 2 diabetes, as well as a higher incidence of reproductive and neurological disorders (170, 171, 174, 175, 181, 182)

Looking ahead, this combination offers the potential to: Improve patient compliance by simplifying treatment protocols Enhance early detection of changes in sleep patterns or OSA severity Promote collaborative care between patients and providers As these solutions gain traction, the future of OSA treatment looks increasingly personalized, data-driven, and effective, offering renewed hope for millions affected by this chronic condition

Optimal outcomes depend on factors including treatment area, number of sessions, and adherence to post-treatment care

The disease progresses with COVID-19-induced cell death of alveolar cells, depending on the viral strain